Launching its Terrosa (teriparatide) rival to Eli Lilly’s Forsteo blockbuster osteoporosis treatment in nine European countries following patent expiry on 19 August failed to make much of an impression on Gedeon Richter’s results in the first nine months of this year. Nevertheless, the Hungarian group was able to increase its Pharmaceutical turnover by 8.1% to €917.1m ($1.012bn) in the period.
Terrosa launches occurring from 20 August in the Hungarian firm’s domestic market, as well as in Austria, the Czech Republic,...



